NCT06117774 (DeLLphi-306) is a Phase 3 clinical trial of Tarlatamab in Limited Stage Small Cell Lung Cancer, sponsored by Amgen.

Who is sponsoring NCT06117774?

NCT06117774 is sponsored by Amgen.

What drugs are being tested in NCT06117774?

Interventions in NCT06117774: Tarlatamab, Placebo.

What condition does NCT06117774 study?

NCT06117774 studies Limited Stage Small Cell Lung Cancer, Small Cell Lung Cancer.

Is NCT06117774 still recruiting?

NCT06117774 is currently recruiting now. Last updated 15 April 2026.

Last reviewed 2026-04-15 · How we verify

NCT06117774: DeLLphi-306

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)

Recruiting now Phase 3 Last updated 15 April 2026

What this trial tests

Phase 3 trial testing Tarlatamab in Limited Stage Small Cell Lung Cancer in 400 participants. Currently enrolling.

Timeline

20 February 2024

Primary endpoint
29 May 2030

29 May 2030

Quick facts

Lead sponsor	Amgen
Phase	Phase 3
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	400
Start date	20 February 2024
Primary completion	29 May 2030
Estimated completion	29 May 2030
Sites	204 locations across Hong Kong, Colombia, Italy, Japan, Taiwan, Poland, South Korea, Belgium

Drugs / interventions tested

Tarlatamab (TARLATAMAB) — full drug profile →
Placebo

Conditions studied

Limited Stage Small Cell Lung Cancer — all drugs for Limited Stage Small Cell Lung Cancer →
Small Cell Lung Cancer — all drugs for Small Cell Lung Cancer →

Sponsor

Amgen — full company profile →

Who can join

18 and older, any sex, with Limited Stage Small Cell Lung Cancer or Small Cell Lung Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The primary objective of this study is to compare the efficacy of tarlatamab with placebo as assessed by progression free survival (PFS) based on blinded independent central review (BCIR) per response evaluation criteria in solid tumors v1.1 (RECIST 1.1) and on prolonging overall survival (OS).

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Antibodies to watch in 2025.
Crescioli S, Kaplon H, Wang L, Visweswaraiah J, et al · · 2025 · cited 87× · PMID 39711140 · DOI 10.1080/19420862.2024.2443538
DLL3-guided therapies in small-cell lung cancer: from antibody-drug conjugate to precision immunotherapy and radioimmunotherapy.
Su PL, Chakravarthy K, Furuya N, Brownstein J, et al · · 2024 · cited 33× · PMID 38730427 · DOI 10.1186/s12943-024-02012-z
Clinical Progresses and Challenges of Bispecific Antibodies for the Treatment of Solid Tumors.
Gu Y, Zhao Q. · · 2024 · cited 16× · PMID 39172329 · DOI 10.1007/s40291-024-00734-w
Bispecific Antibodies in Solid Tumors: Advances and Challenges.
Shan KS, Musleh Ud Din S, Dalal S, Gonzalez T, et al · · 2025 · cited 12× · PMID 40565299 · DOI 10.3390/ijms26125838
Advances in DLL3-targeted therapies for small cell lung cancer: challenges, opportunities, and future directions.
Ding J, Yeong C. · · 2024 · cited 11× · PMID 39703856 · DOI 10.3389/fonc.2024.1504139
10 years of BiTE immunotherapy: an overview with a focus on pancreatic cancer.
Paredes-Moscosso SR, Nathwani AC. · · 2024 · cited 9× · PMID 39759138 · DOI 10.3389/fonc.2024.1429330
Small cell lung cancer: emerging subtypes, signaling pathways, and therapeutic vulnerabilities.
Zhang J, Zeng X, Guo Q, Sheng Z, et al · · 2024 · cited 8× · PMID 39103941 · DOI 10.1186/s40164-024-00548-w
Safety of tarlatamab with 6-8-h outpatient versus 48-h inpatient monitoring during cycle 1: DeLLphi-300 phase 1 substudy.
Chiang AC, Olmedo Garcia ME, Carlisle JW, Dowlati A, et al · · 2025 · cited 7× · PMID 40187110 · DOI 10.1016/j.esmoop.2025.104538

Verify or expand the search:

Other trials of Tarlatamab

Trials testing the same drug.

NCT07531095 — Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC) · Phase 1 · not yet recruiting
NCT07328490 — Bispecific T-Cell Engager Tarlatamab and TROP2 Targeted Antibody Drug Conjugate Sacituzumab Govitecan in Previously Trea · Phase 1, PHASE2 · not yet recruiting
NCT07423585 — Tarlatamab for the Treatment of Extensive Stage Small-cell Lung Cancer · Phase 2 · recruiting
NCT07242547 — Study of Tarlatamab as Maintenance Treatment After Chemo-radiotherapy for Limited Stage SCLC Patients · Phase 2 · recruiting
NCT06937905 — Tarlatamab vs Standard of Care Chemotherapy in Patients With Pre-treated Advanced, Pulmonary or Gastroenteropancreatic P · Phase 3 · recruiting

Other recruiting trials for Limited Stage Small Cell Lung Cancer

Currently open trials in the same condition.

NCT06943235 — Study of Probiotics Combined With Concurrent Hyperfractionated ChemoRadiotherapy and Adebrelimab Immunomaintenance in th · Phase 2 · recruiting
NCT06256237 — Neoadjuvant Therapy With Toripalimab and JS004 Combined With Etoposide and Platinum Chemotherapy for Limited-stage Small · Phase 2 · recruiting
NCT05623267 — Sugemalimab as Consolidation Therapy in Patients With LS-SCLC Following cCRT or sCRT · Phase 2, PHASE3 · recruiting
NCT05443646 — Consolidation Serplulimab Following Concurrent Chemoradiotherapy for LS-SCLC Patients · Phase 2 · recruiting
NCT04829708 — Efficacy and Safety of Prophylactic Cranial Irradiation Versus MRI Surveillance in Patients With Limited-stage Small Cel · Phase 3 · recruiting

Other Amgen trials

Trials by the same sponsor.

NCT07223190 — A Study Evaluating Subcutaneous Versus Intravenous Blinatumomab in Newly Diagnosed Adults With B-cell Precursor Acute Ly · Phase 3 · not yet recruiting
NCT07493512 — Trial of Xaluritamig in Adults With Metastatic Castration-resistant Prostate Cancer · Phase 1 · not yet recruiting
NCT07531095 — Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC) · Phase 1 · not yet recruiting
NCT06987539 — A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in Children With Gen · Phase 2 · recruiting
NCT05909761 — Observational Safety Study in Women With Neuromyelitis Optica Spectrum Disorder (NMOSD) Exposed to UPLIZNA® During Pregn · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06117774 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Amgen
Last refreshed: 15 April 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06117774.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing